Tesamorelin UK: price and NHS access

If you are in the UK and searching for what tesamorelin costs, the pricing question and the regulatory question are the same question. Tesamorelin has no marketing authorisation from the MHRA^[1], no NICE technology appraisal, and no Drug Tariff entry. There is no published UK price because there is no licensed product to price. This article explains why, maps the only legal access route that exists in theory, and provides the US reference cost as the only available published benchmark.

For the mechanism, clinical evidence, and the cross-country regulatory comparison, see the tesamorelin peptide page.

Why no authorised UK price exists

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). In the United States it is marketed as Egrifta SV by Theratechnologies and is FDA-approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.^[6] That is the compound's only approved indication anywhere in the world. It has never held a marketing authorisation in the European Union, the European Economic Area, or the United Kingdom.

In 2012 Ferrer Internacional, the company that had submitted the EU marketing authorisation application, withdrew the application. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had concluded that the data provided did not allow it to reach a positive benefit-risk balance, citing concerns about elevated IGF-1 levels, the absence of long-term safety data, and doubts about clinical meaningfulness in European HIV patients who typically present with smaller abdominal fat deposits than the trial population.^[1] No company has since filed a new application with the EMA or the MHRA.

Without a marketing authorisation, there is no approved price. The MHRA does not set or publish prices for compounds that have not been through the authorisation process. The NHS Drug Tariff covers only licensed pharmacy medicines. NICE technology appraisals apply only to licensed products: the Institute cannot assess a medicine with no defined indication, no approved formulation, and no authorised prescribing population. A search of the NICE guidance database returns no technology appraisal, clinical guideline, or evidence review for tesamorelin.^[1]

The legal definition problem

The Human Medicines Regulations 2012 define a medicinal product as any substance presented as having properties for treating or preventing disease in human beings, or any substance that can be administered to humans to restore, correct, or modify physiological function through pharmacological, immunological, or metabolic action.^[4] Tesamorelin, when sold with the claim that it reduces visceral fat or raises growth hormone levels, fits both limbs of that definition. It is therefore treated in UK law as an unlicensed medicine rather than as a supplement or a research chemical. The consequence is that it cannot lawfully be marketed for human use in the UK without a marketing authorisation.

The specials route: what it is and what it cannot do for most people

There is one legal pathway through which an unlicensed medicine can reach a patient in the UK: the 'specials' route. Under the MHRA specials framework, a licensed UK prescriber can request an unlicensed product for a specific named patient, taking personal clinical responsibility for that decision.^[2] The supplier must hold either a Manufacturer's Specials Licence (for products sourced from outside approved country lists) or a Wholesale Dealer's Licence, and the MHRA must be notified before any import proceeds.^[3]

Pricing through this route is set by the licensed manufacturer or importer, not by any reference framework. Specials are almost always substantially more expensive than equivalent licensed medicines because they are made or sourced in small quantities without the economies of scale that licensed manufacturing produces. There is no cap, no reference price, and no NHS reimbursement mechanism for a special unless the prescriber has secured a separate individual funding request approval.

In practice, the specials route is not a realistic access pathway for tesamorelin in the UK for two related reasons. First, the compound's only approved indication is HIV-associated lipodystrophy in an FDA-licensed, FDA-supervised prescribing context. A UK prescriber invoking the specials route would need to take on full clinical responsibility for a GHRH analogue with a withdrawn EU application, no European prescribing information, and a safety concern about elevated IGF-1 that was the CHMP's primary objection.^[1] Very few HIV specialists in the UK would do that, and no general practitioner would.

Second, the off-label uses driving grey-market tesamorelin demand, mainly anti-ageing protocols and body composition in people without HIV, have no clinical trial evidence in non-HIV populations. The CHMP withdrawal opinion explicitly questioned whether tesamorelin's clinical effect in HIV patients translated to populations with different fat-distribution profiles. That gap is wider still for healthy adults seeking the compound for general growth hormone optimisation.

What grey-market tesamorelin costs

Because tesamorelin is not sold through licensed UK pharmacies and carries no regulated price, any cost figures reflect grey-market observable patterns rather than official data. Grey-market vendors operating through research-chemical websites list tesamorelin, typically as a lyophilised powder, in vials described as 2 mg or 5 mg. Purity, identity, and sterility are unverified; none of these vendors holds an MHRA licence to supply the product as a medicine.

Vendors shipping from outside the UK add a further layer of risk. UK Border Force can seize unlicensed medicines arriving by post. The UK government's guidance on taking medicine in or out of the country specifies that quantities above a three-month personal supply may be confiscated.^[5] Seizure does not automatically produce a criminal prosecution for the buyer, but it does mean the product is lost with no compensation.

These price ranges are informational only. PeptideMethods does not recommend grey-market sourcing, and nothing in this article should be read as an endorsement of any vendor or supply channel.

The US reference price

The only published benchmark for tesamorelin pricing comes from the United States, where Egrifta SV is the licensed product. The approved dose is 1.4 mg subcutaneously once daily^[6], meaning a full month of treatment requires roughly 30 vials at that dose. Egrifta SV is a specialty pharmaceutical distributed through limited specialty pharmacy networks; it is not available at standard retail pharmacies.

US specialty pharmaceutical list prices for Egrifta SV place the monthly cost in the range of several thousand US dollars before insurance. Theratechnologies offers a patient assistance programme for US patients meeting income criteria, which substantially reduces out-of-pocket cost for those who qualify. Neither the list price nor the assistance programme extends outside the United States. For a UK patient, the US commercial channel is not accessible through any standard route, and importing the licensed US product for personal use would still require the specials framework and prescriber authorisation.

We are not citing a specific US dollar figure here because Theratechnologies' published WAC is not readily accessible through a verifiable public source that we can footnote to the primary data. If you are a US patient seeking assistance, the manufacturer's patient support programme is the starting point. If you are a UK reader using this for cost comparison, the key takeaway is that even in the one country where tesamorelin is licensed, it is a high-cost specialty drug distributed through controlled channels, not a commodity medicine.

No NHS reimbursement pathway

NHS reimbursement follows a sequence. A medicine must first obtain a marketing authorisation from the MHRA (or previously the EMA, before the UK left the EU). Once authorised, it can enter the Drug Tariff for straightforward medicines or be submitted to NICE for a technology appraisal for medicines requiring cost-effectiveness review. A positive NICE recommendation creates an NHS commissioning obligation. None of these steps have been reached for tesamorelin.

Scotland, Wales, and Northern Ireland have their own bodies for medicines assessment (the Scottish Medicines Consortium, the All Wales Medicines Strategy Group, and the Northern Ireland Formulary respectively), but the prerequisite is the same across all four nations: a marketing authorisation comes first. Tesamorelin has never reached the first step in the UK.

Private health insurance in the UK also follows the licensed-medicines framework for most policies. An unlicensed medicine without a NICE recommendation would not typically meet the criteria for reimbursement under standard private health insurance. Any cost would be entirely out of pocket.

What we do not yet know

The largest open question is whether the clinical benefit demonstrated in HIV patients extends to other populations at all. The pivotal trials that supported FDA approval were conducted in people with HIV-associated lipodystrophy, a specific metabolic complication of antiretroviral therapy that produces visceral fat accumulation with distinct hormonal features. The CHMP found the trial population too different from European HIV patients to support authorisation even within the HIV indication.^[1] Extrapolating that evidence to people without HIV is a further step with no trial data behind it.

The long-term safety question is also open. The CHMP's concerns about IGF-1 elevation relate to potential long-term risks including cancer and diabetic eye disease complications. The pivotal trials ran to 26 weeks. For a compound expected to require ongoing use, the absence of long-term safety data was a core reason for the EU withdrawal.^[1] That data gap has not been closed in the decade since.

We update this page when the UK regulatory position changes. For the full evidence review and cross-country regulatory comparison, see the tesamorelin peptide page and the UK regulation hub. If you are considering tesamorelin for a specific health goal, that conversation belongs with a clinician who can assess your situation against the evidence available and the regulatory reality in the UK.